Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Non-cash Items: 2023-2025

Historic Non-cash Items for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Sep 2025 value amounting to $15.8 million.

  • Monte Rosa Therapeutics' Non-cash Items rose 282.39% to $15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.8 million, marking a year-over-year increase of 282.39%. This contributed to the annual value of $6.3 million for FY2024, which is 61.69% up from last year.
  • As of Q3 2025, Monte Rosa Therapeutics' Non-cash Items stood at $15.8 million, which was up 95.17% from $8.1 million recorded in Q2 2025.
  • In the past 5 years, Monte Rosa Therapeutics' Non-cash Items ranged from a high of $15.8 million in Q3 2025 and a low of $1.8 million during Q2 2024.
  • Its 3-year average for Non-cash Items is $6.2 million, with a median of $4.7 million in 2023.
  • Per our database at Business Quant, Monte Rosa Therapeutics' Non-cash Items crashed by 47.48% in 2024 and then skyrocketed by 339.87% in 2025.
  • Monte Rosa Therapeutics' Non-cash Items (Quarterly) stood at $4.7 million in 2023, then surged by 140.86% to $11.4 million in 2024, then skyrocketed by 282.39% to $15.8 million in 2025.
  • Its last three reported values are $15.8 million in Q3 2025, $8.1 million for Q2 2025, and $7.5 million during Q1 2025.